Invention Grant
US07517531B2 Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
有权
登革热四价疫苗在登革热类型1,2,3和4的3'-UTR中含有共同的30个核苷酸缺失，或抗原嵌合登革热病毒1,2,3和4
- Patent Title: Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
- Patent Title (中): 登革热四价疫苗在登革热类型1,2,3和4的3'-UTR中含有共同的30个核苷酸缺失，或抗原嵌合登革热病毒1,2,3和4
-
Application No.: US10970640Application Date: 2004-10-21
-
Publication No.: US07517531B2Publication Date: 2009-04-14
- Inventor: Stephen S. Whitehead , Brian R. Murphy , Lewis Markoff , Barry Falgout , Joseph Blaney , Kathryn Hanley
- Applicant: Stephen S. Whitehead , Brian R. Murphy , Lewis Markoff , Barry Falgout , Joseph Blaney , Kathryn Hanley
- Applicant Address: US DC Washington
- Assignee: The United States of America as represented by the Department of Health and Human Services
- Current Assignee: The United States of America as represented by the Department of Health and Human Services
- Current Assignee Address: US DC Washington
- Agency: Knobbe, Martens, Olson & Bear LLP
- Main IPC: A61K39/295
- IPC: A61K39/295 ; C12N7/04
Abstract:
The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (Δ30) in the 3′-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.
Public/Granted literature
Information query
